Principles: In-hospital care of patients with community-acquired pneumonia (CAP) varies across hospitals. Understanding of the underlying factors is the basis for tailored quality improvements. Using data from a randomised controlled Swiss-wide multicentre trial, we compared length of stay (LOS) and other patient outcomes according to (A) the use of a procalcitonin (PCT)-based antibiotic stewardship protocol, (B) institution type (university vs non-university), and (C) historical time period in relation to the introduction of Diagnosis Related Group (DRG) reimbursement (2012).
Methods: We included 784 patients hospitalised with CAP from six institutions into this secondary analysis. We used multivariable regression models adjusted for age, comorbidities and disease severity to determine the influence of institution characteristics on LOS and patient outcomes.
Findings: LOS was significantly shorter in the institution using a PCT-based antibiotic stewardship protocol (9.2 vs 5.3 days; adjusted mean difference 3.92 days; 95% confidence interval [CI] 5.16-2.68) with shorter antibiotic treatment. There was no difference in LOS in university vs non-university hospitals, but antibiotic courses in university-type hospitals were longer (11.0 vs 8.3 days; adjusted mean difference 2.59 days; 95% CI, 1.69-3.49). No significant difference in LOS was found when comparing the time period before and after the introduction of the DRG system in Switzerland.
Conclusions: We found differences in LOS associated with theuse of a PCT-based antibiotic stewardship protocol, which remained robust after multivariable adjustment. Importantly, the type of institution and model of reimbursement did not influence LOS in our CAP cohort. More health services research studies are needed to establish causal effects.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.4414/smw.2016.14337 | DOI Listing |
Infection
December 2024
Institute for Infectious Diseases and Infection Control, Jena University Hospital-Friedrich Schiller University Jena, Jena, Germany.
BMC Geriatr
December 2022
Centre Hospitalier Annecy Genevois, Pringy Metz-Tessy, France.
Background: Treating pneumonia in old patients remains challenging for clinicians. Moreover, bacterial antimicrobial resistance is a major public health threat.
Objective: The PROPAGE study evaluated the interest of a strategy using serial measurements of procalcitonin (PCT) to reduce the duration of antibiotic therapy in old patients with pneumonia.
Am J Health Syst Pharm
May 2023
VA ECHCS, Aurora, CO, and University of Colorado School of Medicine, Aurora, CO, USA.
Purpose: Clinical trials of procalcitonin (PCT)-based algorithms for antibacterial therapy have shown a reduction in antimicrobial use and improved survival. Translation of PCT algorithms to clinical settings has often been unsuccessful. We hypothesized that appropriate utilization of PCT could be improved by implementing an antimicrobial stewardship team (AST) approach to PCT testing.
View Article and Find Full Text PDFExpert Rev Anti Infect Ther
January 2022
Intensive Care Clinical Unit, Hospital Universitario Virgen Macarena, Sevilla, Spain.
Background: Our objective was to assess the impact on mortality, antibacterial therapy duration, and length of stay of using PCT to guide antibiotic cessation in critically ill patients with sepsis or septic shock.
Research Design And Methods: A systematic literature search was performed in PubMed, Embase, ISI Web of Knowledge, BioMed Central, ScienceDirect and the Cochrane Central Register of Controlled Trials, of clinical trials published in English before December 31, 2019. Eligible studies should be carried out in adults at ICU with sepsis, comparing the PCT-guided antimicrobial therapy with standard of care.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!